- Home
- KULR vs CRDF Comparison
KULR vs CRDF Comparison
Compare KULR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- CRDF
- Stock Information
- Founded
- KULR 2013
- CRDF 1999
- Country
- KULR United States
- CRDF United States
- Employees
- KULR N/A
- CRDF N/A
- Industry
- KULR Electrical Products
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KULR Technology
- CRDF Health Care
- Exchange
- KULR Nasdaq
- CRDF Nasdaq
- Market Cap
- KULR 241.0M
- CRDF 233.5M
- IPO Year
- KULR N/A
- CRDF N/A
- Fundamental
- Price
- KULR $6.44
- CRDF $3.97
- Analyst Decision
- KULR Strong Buy
- CRDF Strong Buy
- Analyst Count
- KULR 2
- CRDF 6
- Target Price
- KULR $40.00
- CRDF $11.92
- AVG Volume (30 Days)
- KULR 3.5M
- CRDF 1.6M
- Earning Date
- KULR 08-11-2025
- CRDF 08-07-2025
- Dividend Yield
- KULR N/A
- CRDF N/A
- EPS Growth
- KULR N/A
- CRDF N/A
- EPS
- KULR N/A
- CRDF N/A
- Revenue
- KULR $11,436,983.00
- CRDF $587,000.00
- Revenue This Year
- KULR $87.77
- CRDF N/A
- Revenue Next Year
- KULR $102.93
- CRDF N/A
- P/E Ratio
- KULR N/A
- CRDF N/A
- Revenue Growth
- KULR 16.47
- CRDF N/A
- 52 Week Low
- KULR $1.60
- CRDF $2.01
- 52 Week High
- KULR $43.92
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- KULR 44.50
- CRDF 52.55
- Support Level
- KULR $6.46
- CRDF $3.73
- Resistance Level
- KULR $6.98
- CRDF $4.52
- Average True Range (ATR)
- KULR 0.59
- CRDF 0.30
- MACD
- KULR 0.13
- CRDF -0.02
- Stochastic Oscillator
- KULR 20.63
- CRDF 30.59
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.